Skip to main content

Market Overview

UPDATE: JMP Securities Initiates Coverage On Intra-Cellular Therapies


Jason Butler of JMP Securities initiated coverage of Intra-Cellular Therapies (NASDAQ: ITCI) on Tuesday with a Market Outperform rating and $26 price target.

“Intra-Cellular Therapies is focused on the development of ITI-007, a novel antipsychotic candidate currently in Phase 3 development for the treatment of schizophrenia,” Butler wrote in a note. The analyst adds that ITI-007 demonstrated “significant efficacy” in a 335-patient Phase 2 trial along with a “favorable safety profile.”

Butler anticipates the results of the Phase 3 trial in the fourth quarter 2015 while a second Phase 3 trial should begin in the first half of 2015. The analyst thinks the potential for the drug is “attractive” given a “strong mechanistic rationale and clinical results.”


Related Articles

View Comments and Join the Discussion!

Posted-In: ITI 007 Jason Butler JMP Securities SchizophreniaAnalyst Color Price Target Initiation Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at